Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)
Close on Nov 17, 2026Market cap $9.75BP/E –Yield –
Madrigal Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Madrigal Pharmaceuticals's total assets was $1.24B at Jun 30, 2026. For fiscal 2025 it was $1.26B, up 20.9% from the year before. Over ten years it grew 125.9% a year on average. The highest annual figure on record is $1.26B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26B | +20.9% |
| FY2024 | Dec 31, 2024 | $1.04B | +62.7% |
| FY2023 | Dec 31, 2023 | $640.55M | +76.7% |
| FY2022 | Dec 31, 2022 | $362.57M | +32.6% |
| FY2021 | Dec 31, 2021 | $273.33M | -4.8% |
| FY2020 | Dec 31, 2020 | $287.00M | -35.1% |
| FY2019 | Dec 31, 2019 | $442.06M | -8.9% |
| FY2018 | Dec 31, 2018 | $485.43M | +152.4% |
| FY2017 | Dec 31, 2017 | $192.31M | +366.7% |
| FY2016 | Dec 31, 2016 | $41.21M | +11234.5% |
| FY2015 | Dec 31, 2015 | $363.58K | -99.6% |
| FY2014 | Dec 31, 2014 | $100.68M | +5.7% |
| FY2013 | Dec 31, 2013 | $95.20M | -7.6% |
| FY2012 | Dec 31, 2012 | $103.02M | +143.4% |
| FY2011 | Dec 31, 2011 | $42.32M | -21.7% |
| FY2010 | Dec 31, 2010 | $54.07M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.24B | +22.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.23B | +23.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.26B | +20.9% |
| Q3 FY2025 | Sep 30, 2025 | $1.36B | +26.9% |
| Q2 FY2025 | Jun 30, 2025 | $1.02B | -7.7% |
| Q1 FY2025 | Mar 31, 2025 | $996.63M | -7.9% |
| Q4 FY2024 | Dec 31, 2024 | $1.04B | +62.7% |
| Q3 FY2024 | Sep 30, 2024 | $1.07B | +351.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.10B | +263.6% |
| Q1 FY2024 | Mar 31, 2024 | $1.08B | +225.5% |
| Q4 FY2023 | Dec 31, 2023 | $640.55M | +76.7% |
| Q3 FY2023 | Sep 30, 2023 | $237.96M | +50.0% |
| Q2 FY2023 | Jun 30, 2023 | $302.46M | +39.8% |
| Q1 FY2023 | Mar 31, 2023 | $332.45M | +49.3% |
| Q4 FY2022 | Dec 31, 2022 | $362.57M | +32.6% |
| Q3 FY2022 | Sep 30, 2022 | $158.64M | -47.9% |
| Q2 FY2022 | Jun 30, 2022 | $216.39M | -34.0% |
| Q1 FY2022 | Mar 31, 2022 | $222.66M | -28.1% |
| Q4 FY2021 | Dec 31, 2021 | $273.33M | -4.8% |
| Q3 FY2021 | Sep 30, 2021 | $304.70M | -10.3% |
| Q2 FY2021 | Jun 30, 2021 | $327.96M | -15.6% |
| Q1 FY2021 | Mar 31, 2021 | $309.73M | -24.7% |
| Q4 FY2020 | Dec 31, 2020 | $287.00M | -35.1% |
| Q3 FY2020 | Sep 30, 2020 | $339.62M | -25.6% |
| Q2 FY2020 | Jun 30, 2020 | $388.39M | -17.3% |
| Q1 FY2020 | Mar 31, 2020 | $411.46M | -14.2% |
| Q4 FY2019 | Dec 31, 2019 | $442.06M | -8.9% |
| Q3 FY2019 | Sep 30, 2019 | $456.25M | -6.8% |
| Q2 FY2019 | Jun 30, 2019 | $469.82M | -4.4% |
| Q1 FY2019 | Mar 31, 2019 | $479.56M | +161.4% |
| Q4 FY2018 | Dec 31, 2018 | $485.43M | +152.4% |
| Q3 FY2018 | Sep 30, 2018 | $489.55M | +679.2% |
| Q2 FY2018 | Jun 30, 2018 | $491.53M | +622.1% |
| Q1 FY2018 | Mar 31, 2018 | $183.48M | +354.6% |
| Q4 FY2017 | Dec 31, 2017 | $192.31M | +366.7% |
| Q3 FY2017 | Sep 30, 2017 | $62.83M | +51.4% |
| Q2 FY2017 | Jun 30, 2017 | $68.07M | – |
| Q1 FY2017 | Mar 31, 2017 | $40.36M | – |
| Q4 FY2016 | Dec 31, 2016 | $41.21M | – |
| Q3 FY2016 | Sep 30, 2016 | $41.51M | – |
See a number that looks wrong?